Quick reads

Healthcare investments will match 2016 levels, and biopharma will continue as the strongest sector. Fundraising will come close to 2016 amounts. The current quick pace of investing may lead firms that raised in 2014 or early 2015 to return to the market in 2017, bolstering fundraising. Series A investments in biopharma may drop as funds turn their attention to supporting Series B and later stage companies that are unable to go public. Device and Dx/Tools likely will be stable. The biopharma IPO window will remain open in 2017, anticipating between 28 and 32 IPOs (compared with 28 in 2016). Crossovers will continue to actively push their companies public. At least half of the biopharma M&A big exits will be for early-stage companies, with the total number expected to reach between 18 and 22. After a very slow 2016 (three IPOs), device IPOs will at least double.

In biopharma industry, immuno-oncology will still be the most fast growing sector. In particular, first CAR-T therapies are expected to receive FDA approvals. A new CRISPR-Cas9 method of gene-editing technology to modify patient’s immune cells will be tested in clinics for the first time. Anticancer vaccines and especially DNA vaccine hold great ever-increasing promise. A novel trend to watch in 2017 will be marijuana research. There are already medicine companies that have started eyeing pot in a pharmaceutical space, but experts say 2017 could bring more research to the forefront now that cannabis has become so accepted in the US.

Beside traditional biopharma and Dx/Tools, a hot trend in 2017 will be artificial intelligence (AI) and Big Data. Big Data can help physicians to compare a patient’s data with billions of anonymous, detailed patient records and against the latest findings in world medical research to provide better care. Big Data can predict epidemics, cure disease, improve a quality of life and avoid preventable deaths. AI allows a digital device to recognize objects—like reading a barcode—respond to a request—à la Siri—to make decisions on the data stored in the cloud, such as IBM’s Watson. Watson can help doctors in different diagnostic and evidence-based treatment such as patient risk assessment and oncology.


Image Source: http://1015fm.com.au/2015/12/your-private-health-data-could-be-sold-for-profit-to-anyone-with-money-to-burn/

WeFund Health Weekly

Health technology trends, data, innovations
and opportunities - direct to your inbox.